Cannabis has the strongest evidence for helping with chronic pain, certain types of epilepsy, chemotherapy-induced nausea, and muscle spasticity in multiple sclerosis. The FDA has approved cannabis-derived or synthetic cannabinoid medications for several of these conditions. Beyond those, the picture gets more complicated, with some widely believed benefits holding up better than others under clinical scrutiny.
Chronic Pain
Pain relief is the most common reason people use medical cannabis, and the research backs it up more consistently than for almost any other condition. A systematic review of clinical studies found that CBD alone, or CBD combined with THC, reduced chronic pain by 42% to 66%. That’s a meaningful reduction for people dealing with nerve pain, arthritis, fibromyalgia, or pain from injuries that never fully resolved.
Cannabis works on pain through the body’s endocannabinoid system. THC activates receptors concentrated in the brain and spinal cord, particularly along pathways that process pain signals. When these receptors are activated, they dial down the release of chemical messengers at nerve connections, essentially turning down the volume on pain signaling. CBD appears to work through different, less direct pathways, including reducing inflammation.
Epilepsy and Seizure Disorders
This is where cannabis has its clearest, most dramatic medical win. The FDA approved a purified CBD medication for treating seizures in Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of childhood epilepsy that often don’t respond well to standard medications. In clinical trials involving children who were already taking an average of three anti-seizure drugs and had tried and stopped four others, CBD reduced total seizure frequency by 47% to 56%, compared to 30% with a placebo. Convulsive seizures specifically dropped by 46% to 49%.
Nearly half the children receiving CBD experienced at least a 50% reduction in seizures. For families who have exhausted other options, those numbers represent a genuine change in daily life.
Chemotherapy Nausea and Appetite Loss
Two synthetic cannabinoid medications are FDA-approved for nausea and vomiting caused by cancer chemotherapy, specifically for patients who haven’t responded to standard anti-nausea drugs. A separate approval covers appetite stimulation in people with HIV/AIDS who experience severe weight loss.
The nausea relief is real, but it comes with caveats. These medications have a narrow therapeutic window, meaning the dose that works is close to the dose that causes unpleasant side effects like dizziness, drowsiness, or feeling “too high.” Newer anti-nausea drugs developed since the original cannabinoid approvals are generally better tolerated, and no head-to-head trials have compared them. For appetite stimulation in HIV/AIDS patients, early studies showed promising weight gain, but later analysis revealed that some of that weight was water or fat rather than the lean muscle mass patients actually need.
Muscle Spasticity in Multiple Sclerosis
People with multiple sclerosis often deal with painful muscle stiffness and spasms that limit mobility. A combination of THC and CBD has shown benefit here. THC acts on receptors found along spasticity pathways in the brain and spinal cord, helping to relax involuntary muscle tightness. Importantly, clinical trials lasting six to sixteen weeks found that cannabis extracts improved spasticity without increasing muscle weakness, which is a real concern with MS treatments since the disease itself already causes weakness.
Sleep
Many people use cannabis specifically to fall asleep faster, and it’s one of the most commonly reported reasons for use. However, the objective data is less enthusiastic than user reports might suggest. A polysomnography study measuring actual brain activity during sleep found no significant differences in sleep onset time, time spent in deep sleep, or time spent in REM sleep between chronic cannabis users and non-users. Sleep onset latency changed by only about 1.2%, and REM sleep duration shifted by less than one-third of a percentage point.
That doesn’t necessarily mean cannabis does nothing for sleep. People may feel more relaxed or less anxious at bedtime, which subjectively improves the experience of falling asleep. But the measurable architecture of sleep, the time spent in each stage, doesn’t appear to change much with regular use.
PTSD
This is one of the biggest gaps between public perception and clinical evidence. Several states approve medical cannabis for PTSD, and many veterans report using it to manage symptoms like nightmares and hyperarousal. But the research consistently fails to show lasting benefit. The only randomized controlled trial comparing whole-plant cannabis to a placebo in 80 military veterans found no significant difference in PTSD symptom reduction between any active cannabis preparation (high THC, high CBD, or a balanced mix) and placebo.
A separate study found that people with PTSD experienced short-term symptom relief while using cannabis but no long-term improvement. Other research suggests chronic use may actually worsen trauma-related symptoms over time. The VA’s clinical practice guidelines, updated in 2023, formally recommend against cannabis for PTSD treatment. People may genuinely feel better in the moment after using cannabis, but repeated use can lead to tolerance as receptor density decreases, creating a cycle where more is needed for the same perceived relief.
Glaucoma
Cannabis does lower eye pressure, which is the key risk factor in glaucoma. But the effect lasts only three to four hours. To maintain a meaningful reduction, you’d need to take 18 to 20 milligrams of THC six to eight times a day, every day. At that level, you couldn’t drive, work, or think clearly. The cost alone would be prohibitive for most people.
There’s also a physiological catch. Cannabis lowers blood pressure throughout the body, which can reduce blood flow to the optic nerve. Since low blood flow to the optic nerve is itself a cause of glaucoma damage, cannabis could cancel out the benefit of lower eye pressure. CBD specifically may actually increase eye pressure, potentially making glaucoma worse. Standard glaucoma eye drops are far more practical and effective.
How Cannabis Works in the Body
Your body has its own cannabinoid system with two main types of receptors. CB1 receptors are among the most abundant receptors in the brain, concentrated in areas controlling memory, movement, coordination, and pain processing. CB2 receptors are found primarily in immune cells and become more active during inflammation. THC directly activates CB1 receptors, which is why it affects pain perception, mood, appetite, and coordination all at once. It acts as a partial activator, meaning it doesn’t fully switch on the receptor the way the body’s own cannabinoids do, which accounts for its variable effects.
CBD doesn’t appear to activate CB1 receptors directly. Its mechanisms are less well understood but seem to involve anti-inflammatory and antioxidant effects, along with interactions at other receptor sites throughout the nervous system. This is why CBD doesn’t produce the “high” associated with THC but can still affect seizures, pain, and inflammation.
Side Effects and Risks
Common side effects include dry mouth, red eyes, dizziness, drowsiness, fatigue, and difficulty focusing. Some people experience nausea, anxiety, or a racing heartbeat. High doses of CBD (above 300 milligrams daily) can cause digestive problems and liver issues. Long-term heavy use carries a risk of cannabinoid hyperemesis syndrome, a condition involving severe, repeated vomiting that can require emergency care.
Certain groups face higher risks. People with bipolar disorder may experience mania. Those with schizophrenia face an elevated risk of psychosis. Cannabis use during pregnancy is linked to preterm birth and low birth weight. People with active heart disease should avoid it, as should anyone within two weeks of surgery requiring general anesthesia, since cannabis can increase the amount of anesthetic needed and raise the risk of complications like rapid heart rate.
Current Legal Status
As of early 2026, the federal landscape is shifting. The Justice Department has moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, down from Schedule I. An expedited hearing process beginning in June 2026 will evaluate broader rescheduling of cannabis itself from Schedule I to Schedule III. Schedule III classification means the federal government recognizes accepted medical use, which could open doors for insurance coverage and expanded research. State medical marijuana programs continue to operate under their own rules, with qualifying conditions varying widely from state to state.